Current stock page

Financial Data

ADMA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ADMAADMA Biologics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$13.68+$0.44 (+3.32%)

Latest quote

  • Momentum
    91
  • Value
    80
  • Quality
    72
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$141.1M$124.4M$114.49M$139.16M$134.22M$121.98M$114.8M$117.55M
Gross Profit$99.92M$86.28M$80.75M$88.82M$75.63M$67.23M$61.1M$63.33M
Operating Income$67.76M$52.45M$50.29M$62.75M$51.01M$42.8M$34.88M$38.32M
Net Income$49.88M$37.82M$45.33M$49.38M$36.43M$34.22M$26.9M$111.9M
EPS$0.22$0.17$0.19$0.21$0.15$0.14$0.11$0.47
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$17.37M$29.54M$58.25M$35.64M$13.29M$21.14M-$19.68M$50.22M
Capital Expenditure-$2M-$2.26M-$2.54M-$1.08M-$14.37M-$2.42M-$4.7M-$2.76M
Free Cash Flow$15.37M$27.28M$55.71M$34.56M-$1.08M$18.72M-$24.38M$47.46M
Net Cash Provided By Operating Activities$17.37M$29.54M$58.25M$35.64M$13.29M$21.14M-$19.68M$50.22M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$732.49M$684.21M$665.18M$624.24M$568.69M$558.38M$510.57M$488.68M
Total Debt$202.8M$203.84M$204.41M$79.89M$83.12M$83.83M$82.01M$82.12M
Cash And Cash Equivalents$124.56M$136.02M$138.15M$87.63M$61.39M$90.29M$71.63M$103.15M
Total Liabilities$293.98M$276M$274.86M$146.92M$137.5M$160.06M$137.15M$139.66M
Total Stockholders Equity$438.51M$408.21M$390.33M$477.32M$431.19M$398.33M$373.42M$349.02M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio12.9712.6214.6326.0217.9522.0627.9423.27
P/B ratio5.45.236.28.018.7211.5715.4713.18
P/S ratio5.89———————
Debt To Equity0.460.50.520.170.190.210.220.24
Free Cash Flow Yield5.62%5.46%4.46%0.73%1.08%1.43%1.57%2.40%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio12.9712.6214.6326.0217.9522.0627.9423.27
P/B ratio5.45.236.28.018.7211.5715.4713.18
P/S ratio5.89———————
Return On Equity41.60%41.39%42.36%30.78%48.57%52.45%55.37%56.64%
Debt To Equity0.460.50.520.170.190.210.220.24

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe17.32x
Pb6.98x
Revenue Growth Yoy5.12%
EPS Growth Yoy46.67%
Gross Margin68.53%
Operating Margin44.93%
ROE42.56%
ROIC28.23%
Debt To Equity0.46
FCF Yield4.38%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$13.68
Volume4.16M
RSI (14)71.04
MACD0.78
MACD signal0.6
MACD histogram0.18
ADX (14)33.96
SMA (50)$10.58
SMA (200)$10.73
ATR (14)$0.66
Historical volatility (annualized)102.27%
Volume (20-day average)4.13M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score56/100
Beta-0.09
Annual volatility58.93%
Max Drawdown-62.71%
Sharpe Ratio-0.01
VaR (95%, 1-day)-4.34%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ADMA Financial Data FAQ

What is ADMA Biologics, Inc.'s revenue?

ADMA Biologics, Inc.'s revenue is one of the core financial data points for ADMA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is ADMA Biologics, Inc.'s revenue growing?

Revenue growth shows whether ADMA Biologics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ADMA's EPS?

ADMA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is ADMA Biologics, Inc.'s net income?

ADMA Biologics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does ADMA Biologics, Inc. generate?

Free cash flow shows how much cash ADMA Biologics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does ADMA Biologics, Inc. have?

Cash and debt help frame ADMA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.